Long-Term Fatigue Can Persist for Up to a Year After a Mini-Stroke

New research reveals that fatigue can last up to a year after a transient ischemic attack, highlighting the importance of follow-up care for TIA patients.
Transient ischemic attacks (TIAs), commonly known as 'ministrokes,' can have lasting effects beyond the immediate neurological symptoms. Recent research indicates that more than half of individuals who experience a TIA may suffer from fatigue that persists for up to a year after the event. The study highlights the importance for healthcare providers to monitor and address fatigue in TIA patients, as it can significantly impact recovery and quality of life.
The research, published in Neurology and conducted by Danish researchers, involved tracking fatigue levels in patients shortly after their TIA and during follow-up visits at 3, 6, and 12 months. Results showed that over 60% of patients experienced pathological fatigue at the start of the study, with more than half continuing to report fatigue after a year. Interestingly, factors such as the presence of acute infarction or a history of anxiety or depression played a role in fatigue outcomes.
This study underscores the need to reconsider post-TIA care, emphasizing ongoing fatigue assessment and management. Healthcare professionals are encouraged to incorporate fatigue evaluations into follow-up protocols, as early identification and intervention could improve long-term outcomes. Experts suggest that rehabilitation and support should be extended to TIA patients similarly to stroke patients, given the comparable fatigue levels observed.
Continued research is necessary to understand why some individuals develop prolonged fatigue after a TIA, and how best to support recovery in these cases.
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Increasing Trends in Nonfatal Fentanyl Overdose Emergency Visits Through Q3 2023
Recent CDC research reveals a significant increase in nonfatal fentanyl overdose ED visits through the third quarter of 2023, highlighting ongoing public health concerns and the need for targeted interventions.
Enhancing Blood Cancer Immunotherapy Through Innovative Modification
Brazilian researchers have developed an improved CAR-T cell therapy by inhibiting the PRC2 complex, resulting in more effective treatment for resistant blood cancers such as lymphoma and leukemia.